Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected populations. Historically, GLP-1RA therapy has relied on injectable peptide agonists (e. g. , liraglutide, semaglutide, dulaglutide, and exenatide), which mimic native incretin biology but require parenteral administration and cold-chain logistics. In parallel, oral GLP-1RAs have emerged through two distinct strategies: (1) the oral delivery of peptide agonists using absorption enhancers (e. g. , oral semaglutide) and (2) true small-molecule, non-peptide GLP-1 receptor agonists (e. g. , orforglipron), designed to be orally bioavailable without peptide constraints. This narrative review compares small-molecule oral GLP-1RAs to injectable peptide agonists across efficacy (glycated hemoglobin HbA1c lowering, weight reduction, and cardiometabolic outcomes), safety and tolerability (gastrointestinal GI adverse events, gallbladder disease, pancreatitis signals, retinopathy considerations, and rare hepatic signals), real-world adherence, and future innovation. Recent phase 3 evidence suggests that oral small-molecule GLP-1RAs can deliver glycemic and weight benefits approaching injectable standards, while high-dose oral peptide formulations may broaden oral options for obesity management. Remaining challenges include long-term outcome data, the optimization of titration to improve tolerability, and equitable access amid rapid market expansion.
Digantkumar Patel (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: